Research and development
Flow – sum over the period · $M
Q3 FY2026
78.5$M
All values (23)
| Period | Value ($M) | Status |
|---|---|---|
| Q1 FY2027 | 114.5 | reported |
| Q4 FY2026 | 90.5 | derived |
| Q3 FY2026 | 78.5 | reported |
| Q2 FY2026 | 57.9 | reported |
| Q1 FY2026 | 52.4 | reported |
| Q4 FY2025 | 48.5 | derived |
| Q3 FY2025 | 36.3 | reported |
| Q2 FY2025 | 31.7 | reported |
| Q1 FY2025 | 30.4 | reported |
| Q4 FY2024 | 26.9 | derived |
| Q3 FY2024 | 24.2 | reported |
| Q2 FY2024 | 21.7 | reported |
| Q1 FY2024 | 22.6 | reported |
| Q4 FY2023 | 21.4 | derived |
| Q3 FY2023 | 20.5 | reported |
| Q2 FY2023 | 18.2 | reported |
| Q1 FY2023 | 16.7 | reported |
| Q4 FY2022 | 15.5 | derived |
| Q3 FY2022 | 11.0 | reported |
| Q2 FY2022 | 11.8 | reported |
| Q1 FY2022 | 9.7 | reported |
| Q4 FY2021 | 8.2 | derived |
| Q3 FY2021 | 7.0 | reported |
| Q1 FY2016 – Q2 FY2021 | – | missing (22 periods): No verified SEC value extracted, although the company reports this metric in other periods. |
Show reported periods only · CSV with all sources · Technical ID: rnd
More metrics for Credo
Income statement
Balance sheet
Sources & calculation
- Value
- $78.0M
- Period
- Q3 FY2026, ended Jan 31, 2026 · quarterly value (3 months, not cumulative)
- Source
- 10-Q, filed Mar 3, 2026 · 0001628280-26-014017
- Location
- us-gaap:ResearchAndDevelopmentExpense
- Confidence
- 1. – directly from an XBRL fact in the filing (or calculated exactly from it)
Versions
| v1 | $78.0M | Mar 3, 2026 | 10-Q 0001628280-26-014017 | reported · confidence 1. · current |